Eisai Executive and Leadership Team

Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching strategic vision and scientific research initiatives for the organization. By overseeing the development of complex pharmaceutical products like Aricept and Lenvima, Imai ensures that the company maintains a competitive edge in the global oncology and neurology sectors. This leadership role involves constant collaboration with the Board to align research priorities with long-term market needs. Toshio Imai drives the integration of advanced molecular targeted medicine into the existing product portfolio, fostering innovation across all therapeutic areas. Through rigorous oversight of scientific protocols, the President & Chief Executive Officer & Scientific Chief & Officer guarantees that every drug candidate meets stringent safety and efficacy standards. Ultimately, Imai secures the future of the company by balancing immediate operational demands with the pursuit of breakthrough medical discoveries that address unmet patient needs.

Nadine Bouali, the Senior Associate, Corporate Strategy, Chief Operating Officer Office at Eisai, manages the operational alignment between strategic planning and daily execution. By analyzing market trends for products like Dayvigo and Pariet, Bouali optimizes internal processes to support the broader corporate mission. This role requires close coordination with the Chief Operating Officer to streamline workflows and enhance organizational efficiency across international regions. Nadine Bouali executes high-level strategic initiatives that strengthen the market position of the company in the pharmaceutical landscape. Through the implementation of data-driven decision-making frameworks, the Senior Associate, Corporate Strategy, Chief Operating Officer Office ensures that resources are allocated effectively to support growth. By monitoring performance metrics and identifying potential operational bottlenecks, Bouali facilitates seamless communication between departments, ultimately driving the success of the company through disciplined strategic management and operational excellence.

Shaji Procida, the President & Chief Operating Officer at Eisai, oversees the daily business operations and the commercialization of the extensive pharmaceutical portfolio. By managing the supply chain and distribution networks for products like Fycompa and Halaven, Procida ensures that essential medications reach patients efficiently across diverse global markets. This leadership position involves coordinating with various department heads to maintain high standards of manufacturing and quality control. Shaji Procida drives the operational strategy that supports the company's commitment to treating complex diseases such as rheumatoid arthritis and peripheral neuropathy. Through the optimization of internal systems, the President & Chief Operating Officer enhances the overall productivity of the organization. By fostering a culture of accountability and precision, Procida ensures that the company meets its financial and operational targets while continuing to provide high-quality healthcare solutions to the global community.

Michael De, the President, Eisai Machinery (USA) at Eisai, directs the specialized machinery division focused on supporting the pharmaceutical manufacturing infrastructure. By overseeing the design and implementation of advanced equipment, De ensures that the production of critical medications remains efficient and compliant with international standards. This role involves managing North American operations to provide technical support and innovative solutions for the broader pharmaceutical industry. Michael De drives the development of high-precision machinery that facilitates the creation of complex drug formulations. Through strategic oversight of the machinery division, the President, Eisai Machinery (USA) contributes to the overall reliability of the supply chain. By collaborating with engineering teams and external partners, De ensures that the company maintains its reputation for technical excellence and operational integrity, ultimately supporting the delivery of life-saving treatments to patients worldwide through superior manufacturing capabilities.

Cynthia Schwalm, the President at Eisai, leads the strategic expansion and market development efforts for the organization. By focusing on the commercial success of the diverse product range, including OTC drugs like Chocola BB plus, Schwalm ensures that the company effectively reaches its target demographics. This leadership role involves navigating complex regulatory environments and building strong relationships with key stakeholders to support long-term growth. Cynthia Schwalm drives the implementation of market-entry strategies that enhance the visibility and accessibility of the company's pharmaceutical offerings. Through the oversight of regional initiatives, the President ensures that the organization remains responsive to the evolving needs of the healthcare sector. By championing a patient-first approach, Schwalm aligns the commercial objectives of the company with the broader mission of improving health outcomes, ultimately securing a sustainable and impactful presence in the competitive global pharmaceutical market.